BUND FINANCE › Stocks › ARGX
argenx SE (ARGX)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +2.42% above its 50-day average.
- It is +9.31% above its 200-day average (long-term uptrend).
- It sits at 68% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$1.1B | US$410.7M | US$1.2B | US$2.2B | US$4.2B |
| Net income | −US$408.3M | −US$709.6M | −US$295.1M | US$833.0M | US$1.3B |
| EPS (diluted) | -7.99 | -13.05 | -5.16 | 12.78 | 19.63 |
| Gross margin | 46.1% | 92.8% | 90.4% | 89.6% | 89.2% |
| Operating margin | -32.4% | -175.4% | -34.7% | -1.0% | 25.4% |
| Net margin | -37.9% | -172.8% | -24.1% | 38.0% | 31.1% |
| Free cash flow | −US$728.2M | −US$966.6M | −US$464.1M | −US$151.0M | US$679.0M |
| Total debt | US$11.5M | US$12.4M | US$20.0M | US$39.1M | US$83.5M |
| Cash | US$1.3B | US$800.7M | US$2.0B | US$1.5B | US$3.5B |
Compound annual growth: revenue 40.1% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 23.3x | 42.0x | 26.4x |
| EV / EBITDA | 19.9x | 186.4x | 16.3x |
| Operating margin | 27.5% | — | 3.6% |
| Net margin | 30.3% | — | -0.0% |
| Debt / equity | 0.19 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About argenx SE
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, wi…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice